Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment.
cholestasis
enoxaparin
hepatitis
toxicity
transaminases
Journal
Advances in laboratory medicine
ISSN: 2628-491X
Titre abrégé: Adv Lab Med
Pays: Germany
ID NLM: 9918284273306676
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
18
05
2021
accepted:
19
09
2021
medline:
3
11
2021
pubmed:
3
11
2021
entrez:
26
6
2023
Statut:
epublish
Résumé
Treatment with low-molecular-weight heparins is very common in clinical practice. Exceptionally, some patients develop hepatitis within a few days of starting treatment, and rapid discontinuation of the drug is decisive to avoid chronification. These episodes usually present themselves only with elevated transaminases. We describe the case of a patient who presented a cholestatic pattern, which is very uncommon with this type of drug. Hepatitis secondary to heparin therapy is an underdiagnosed entity. The laboratory plays a fundamental role in its diagnosis, given that it initially presents itself without a clear clinical profile.
Identifiants
pubmed: 37360893
doi: 10.1515/almed-2021-0048
pii: almed-2021-0048
pmc: PMC10197442
doi:
Types de publication
Case Reports
Langues
eng
spa
Pagination
575-582Informations de copyright
© 2021 Guillermo Velasco de Cos et al., published by De Gruyter, Berlin/Boston.
Déclaration de conflit d'intérêts
Competing interests: Authors state no conflict of interest.
Références
J Pharm Technol. 2019 Feb;35(1):36-40
pubmed: 34861027
J Clin Epidemiol. 1993 Nov;46(11):1323-30
pubmed: 8229110
J Clin Pharmacol. 2020 Dec;60(12):1671-1678
pubmed: 32639644
Am J Health Syst Pharm. 2009 Apr 1;66(7):638-41
pubmed: 19299370
Pharmacotherapy. 2001 Jan;21(1):108-13
pubmed: 11191729
Drug Saf Case Rep. 2015 Dec;2(1):17
pubmed: 27747729
Case Rep Gastroenterol. 2020 Jun 10;14(2):315-319
pubmed: 32595436
Expert Rev Hematol. 2017 Jul;10(7):595-605
pubmed: 28632418
Gastroenterol Hepatol. 2015 Aug-Sep;38(7):438-9
pubmed: 25155866